Integration of global spectral karyotyping, CGH arrays, and expression arrays reveals important genes in the pathogenesis of glioblastoma multiforme

Annals of Surgical Oncology

Volumn 19, Issue 7, 2012, Pages 2367-2379

  Leone, Paola E ^a,b   Gonzalez, M Belén ^a   Elosua, Carolina ^b   Gómez Moreta, Juan A ^c   Lumbreras, Eva ^a   Robledo, Cristina ^a   Santos Briz, Angel ^c   Valero, José Maria ^c   De La Guardia, Rafael Díaz ^b   Gutierrez, Norma C ^a,c   Hernandez, Jesus M ^a,c   García, Juan L ^a,c  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b Centro de Investigaciones Biomedicas (CIBM)   (Spain)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CACNA2D3 PROTEIN; MAST3 PROTEIN; PPP2R2B PROTEIN; PPP6C PROTEIN; PROM1 PROTEIN; PROTEIN; SIK PROTEIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARRAY COMPARATIVE GENOMIC HYBRIDIZATION; ARTICLE; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION ANALYSIS; GENE EXPRESSION SYSTEM; GENE TRANSLOCATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PATHOGENESIS; SPECTRAL KARYOTYPING;

ADULT; AGED; CASE-CONTROL STUDIES; CHROMOSOME ABERRATIONS; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMANS; KARYOTYPING; MALE; MIDDLE AGED; NEOPLASM GRADING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; SPECTRAL KARYOTYPING; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84865123671     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2202-5     Document Type: Article

References (61)

1. Luois DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. World Health Organization classification of tumours of the central nervous system. 4th ed. Lyon: IARC/WHO, 2007.
2. Mitelman F, Johannson B, Mertenens F, editors. Mitelman database of chromosome aberrations and gene fusions in cancer. http://cgap.nci.nih.gov/ Chromosomes/Mitelman.
3. Koschny R, Koschny T, Froster UG, Krupp W, Zuber MA. Comparative genomic hybridization in glioma: a meta-analysis of 509 cases. Cancer Genet Cytogenet. 2002;135:147-59. (Pubitemid 34786766)
4. Krex D, Mohr B, Hauses M, Ehninger G, Schackert HK, Schackert G. Identification of uncommon chromosomal aberrations in the neuroglioma cell line H4 by spectral karyotyping. J Neurooncol. 2001;52:119-28. (Pubitemid 32691174)
5. Krex D, Mohr B, Appelt H, Schackert HK, Schackert G. Gene analysis of a multifocal glioblastoma multiforme: a suitable tool to gain new aspects in glioma development. Neurosurgery. 2003;53:1377-84. (Pubitemid 37484867)
6. Kubota H, Nishizaki T, Harada K, et al. Identification of recurrent chromosomal rearrangements and the unique relationship between low-level amplification and translocation in glioblas-toma. Genes Chromosomes Cancer. 2001;31:125-33. (Pubitemid 32411038)
7. Squire JA, Arab S, Marrano P, et al. Molecular cytogenetic analysis of glial tumors using spectral karyotyping and comparative genomic hybridization. Mol Diagn. 2001;6:93-108. (Pubitemid 32622694)
8. Cowell JK, Matsui S, Wang YD, et al. Application of bacterial artificial chromosome array-based comparative genomic hybridization and spectral karyotyping to the analysis of glioblastoma multiforme. Cancer Genet Cytogenet. 2004;151:36-51. (Pubitemid 38569631)
9. Loja T, Chlapek P, Kuglik P, et al. Characterization of a GM7 glioblastoma cell line showing CD133 positivity and both cyto-plasmic and nuclear localization of nestin. Oncol Rep. 2009;21: 119-27.
10. Zuber MA, Krupp W, Holland H, Froster UG. Characterization of chromosomal aberrations in a case of glioblastoma multiforme combining cytogenetic and molecular cytogenetic techniques. Cancer Genet Cytogenet. 2002;138:111-15. (Pubitemid 36020464)
11. Nord H, Hartmann C, Andersson R, et al. Characterization of novel and complex genomic aberrations in glioblastoma using a 32 K BAC array. Neurooncology. 2009;11:803-18.
12. Yin D, Ogawa S, Kawamata N, et al. High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. Mol Cancer Res. 2009;7:665-77.
13. Rao SK, Edwards J, Joshi AD, Siu IM, Riggins GJ. A survey of glioblastoma genomic amplifications and deletions. J Neuroon-col. 2010;96:169-79.
14. Idbaih A, Criniere E, Ligon KL, Delattre O, Delattre JY. Array-based genomics in glioma research. Brain Pathol. 2010;20: 28-38.
15. Misra A, Pellarin M, Nigro J, et al. Array comparative genomic hybridization identifies genetic subgroups in grade 4 human astrocytoma. Clin Cancer Res. 2005;11:2907-18. (Pubitemid 40525192)
16. Nigro JM, Misra A, Zhang L, et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res. 2005;65:1678-86. (Pubitemid 40478592)
17. Korshunov A, Sycheva R, Golanov A. Genetically distinct and clinically relevant subtypes of glioblastoma defined by array-based comparative genomic hybridization (array-CGH). Acta Neuropathol. 2006;111:465-74.
18. Maher EA, Brennan C, Wen PY, et al. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glio-blastoma entities. Cancer Res. 2006;66:11502-13. (Pubitemid 46009984)
19. Idbaih A, Marie Y, Lucchesi C, et al. BAC array CGH disting-ishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer. 2008;122:1778-86. (Pubitemid 351413424)
20. Mulholland PJ, Fiegler H, Mazzanti C, et al. Genomic profiling identifies discrete deletions associated with translocations in glioblastoma multiforme. Cell Cycle. 2006;5:783-91.
21. Ruano Y, Mollejo M, Ribalta T, et al. Identification of novel candidate target genes in amplicons of glioblastoma multiforme tumors detected by expression and CGH microarray profiling. Mol Cancer. 2006;26:39.
22. de Tayrac M, Etcheverry A, Aubry M, et al. Integrative genome-wide analysis reveals a robust genomic glioblastoma signature associated with copy number driving changes in gene expression. Genes Chromosomes Cancer. 2009;48:55-68.
23. Hodgson JG, Yeh RF, Ray A, et al. Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Neurooncology. 2009;11:477-87.
24. Ernst A, Hofmann S, Ahmadi R, et al. Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Clin Cancer Res. 2009;15:6541-50.
25. Lo KC, Rossi MR, LaDuca J, et al. Candidate glioblastoma development gene identification using concordance between copy number abnormalities and gene expression level changes. Genes Chromosomes Cancer. 2007;46:875-94. (Pubitemid 47435018)
26. Wiedemeyer R, Brennan C, Heffernan TP, et al. Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell. 2008, 13:355-64. (Pubitemid 351454058)
27. Gardina PJ, Lo KC, Lee W, Cowell JK, Turpaz Y. Ploidy status and copy number aberrations in primary glioblastomas defined by integrated analysis of allelic ratios, signal ratios and loss of het-erozygosity using 500 K SNP mapping arrays. BMC Genomics. 2008;17:489.
28. TCGA: The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061-68.
29. Ducray F, Idbaih A, de Reyniès A, et al. Anaplastic oligoden-drogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer. 2008;20:41.
30. Verhaak RG, Hoadley KA, Purdom E, et al. Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98-110.
31. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol. 1993;3:255-68. (Pubitemid 23276692)
32. Qi H, Dal Cin P, Hernandez JM, et al. Trisomies 8 and 20 in desmoid tumors. Cancer Genet Cytogenet. 1996;92:147-9. (Pubitemid 26427679)
33. Robledo C, García JL, Caballero D, et al; Spanish Lymphoma/Autologous Bone Marrow Transplant Study Group (GEL-TAMO). Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas. Cancer. 2009;115:3728-37.
34. Hermsen M, Snijders A, Alonso Guervós M, et al. Centromeric chromosomal translocations show tissue-specific differences between squamous cell carcinomas and adenocarcinomas. Oncogene. 2005;24:1571-9. (Pubitemid 40396087)
35. Qin YR, Fu L, Sham PC, et al. Single-nucleotide polymorphism-mass array reveals commonly deleted regions at 3p22 and 3p14.2 associate with poor clinical outcome in esophageal squamous cell carcinoma. Int J Cancer. 2008;123:826-30. (Pubitemid 352032408)
36. Tai AL, Mak W, Ng PK, et al. High-throughput loss-of-hetero-zygosity study of chromosome 3p in lung cancer using single-nucleotide polymorphism markers. Cancer Res. 2006;66:4133-8.
37. Hanke S, Bugert P, Chudek J, Kovacs G. Cloning a calcium channel a2d-3 subunit gene from a putative tumor suppressor gene region at chromosome 3p21.1 in conventional renal cell carcinoma. Gene. 2001;264:69-75. (Pubitemid 32195489)
38. Wanajo A, Sasaki A, Nagasaki H, et al. Methylation of the calcium channel-related gene, CACNA2D3, is frequent and a poor prognostic factor in gastric cancer. Gastroenterology. 2008;135:580-90.
39. Thorell K, Bergman A, Carén H, et al. Verification of genes differentially expressed in neuroblastoma tumours: a study of potential tumour suppressor genes. BMC Med Genomics. 2009;2:53.
40. Johannsdottir HK, Jonsson G, Johannesdottir G, et al. Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors. Int J Cancer. 2006;119:1052-60. (Pubitemid 44116912)
41. Hashimoto YK, Satoh T, Okamoto M, Takemori H. Importance of autophosphorylation at Ser186 in the A-loop of salt inducible kinase 1 for its sustained kinase activity. J Cell Biochem. 2008;104:1724-39.
42. Garland P, Quraishe S, French P, O'Connor V. Expression of the MAST family of serine/threonine kinases. Brain Res. 2008;1195: 12-9.
43. Bastians H, Ponstingl H. The novel human protein serine/threo-nine phosphatase 6 is a functional homologue of budding yeast Sit4p and fission yeast ppe1, which are involved in cell cycle regulation. J Cell Sci. 1996;109:2865-74. (Pubitemid 27029257)
44. Bhatia M. AC133 expression in human stem cells. Leukemia. 2001;15:1685-8. (Pubitemid 33061833)
45. Looijenga LH, Hersmus R, Gillis AJ, et al. Genomic and expression profiling of human spermatocytic seminomas: primary spermatocyte as tumorigenic precursor and DMRT1 as candidate chromosome 9 gene. Cancer Res. 2006;66:290-302. (Pubitemid 43166035)
46. Gashaw I, Dushaj O, Behr R, et al. Novel germ cell markers characterize testicular seminoma and fetal testis. Mol Hum Re-prod. 2007;13:721-7. (Pubitemid 47543410)
47. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313-23. (Pubitemid 47355323)
48. Yin S, Li J, Hu C, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 2007;120:1444-50. (Pubitemid 46355378)
49. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodefi-cient mice. Nature. 2007;445:106-10. (Pubitemid 46067310)
50. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111-5. (Pubitemid 46067311)
51. Ieta K, Tanaka F, Haraguchi N, et al. Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol. 2008;15:638-48. (Pubitemid 351643025)
52. Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008;15:504-14. (Pubitemid 351267301)
53. Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA. 2003;100:15178-83. (Pubitemid 37518036)
54. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821-8. (Pubitemid 37187480)
55. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396-401. (Pubitemid 39551674)
56. Yuan X, Curtin J, Xiong Y, et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene. 2004;23:9392-400. (Pubitemid 40069671)
57. Nishide K, Nakatani Y, Kiyonari H, Kondo T. Glioblastoma formation from cell population depleted of Prominin1-expressing cells. PLoS ONE. 2009;4:e6869.
58. ? GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas. BMC Cancer. 2010;10:454.
59. Pallini R, Ricci-Vitiani L, Banna GL, et al. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res. 2008;14:8205-12.
60. Zhang M, Song T, Yang L, et al. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res. 2008;27:85.
61. Kappadakunnel M, Eskin A, Dong J, et al. Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone. J Neurooncol. 2010;96:359-67.